“XG Sciences has been working with Aspen Capital since early 2013. They closed their first investment quickly after signing a term sheet and have been a trusted partner ever since. In addition to participating in every financing since then, either directly or through one of their affiliates, they have been instrumental in helping to refine our focus and attract world class partners, Board Members and investors. This has helped us significantly increase our valuation and positioned us well to pursue an Initial Public Offering in the next 12-24 months. Steven Jones has been an investor for nine years and a Board Member for the last six years, and he is just as involved today as he was in the beginning.“

“Steve Jones of Aspen Capital was instrumental in the growth and development of NeoGenomics. Aspen closed its first investment in 2003 and continued to invest for years as the Company required growth capital. In addition, Steve was deeply involved in helping NeoGenomics refine its business model and strategy, and execute many strategic initiatives. Today, NeoGenomics is a recognized leader in Oncology Diagnostics with a market capitalization over $2 billion and Steve remains a trusted member of our Board.”